In this review the current overall knowledge on hepatitis A, B, C, D, and E will be discussed.
These diseases are all characterized by liver inflammation but have significant differences in …

HCV infection, risk-based screening failed to identify the majority of individuals with HCV
infection due to both clinician and patient barriers.(9-12) Analysis of the 2003-2010 National …

Methods This summary of seven separate smaller real-world studies aims to validate the
results seen in EXPEDITION-8 and provide an up-to-date real-world reference for clinicians …

Dr. Aronsohn has no relevant financial affiliations to disclose (updated November 12, 2019).
Dr. Bhattacharya has no relevant financial affiliations to disclose (updated November 13 …

Introduction The EXPEDITION-8 clinical trial has demonstrated that treatment-naïve patients
with compensated cirrhosis (TN/CC) of HCV genotypes 1–6 can achieve a 98% intent-to …

Background & Aims The direct-acting antiviral combination glecaprevir/pibrentasvir has
been approved by the Food and Drug Administration for 8 weeks of treatment in treatment …

Abstract Background & Aims Large‐scale data regarding the real‐world effectiveness and
safety of glecaprevir/pibrentasvir (GLE/PIB) for patients with chronic hepatitis C virus (HCV) …

The study evaluated the real-world treatment outcomes of Glecaprevir/pibrentasvir
(GLE/PIB) including effectiveness, safety and healthcare resource utilization based on a …

Introduction Glecaprevir/pibrentasvir is approved for treating chronic hepatitis C virus (HCV)
genotypes (GT) 1–6. We evaluated real-world effectiveness, safety, and patient-reported …

Introduction An unsafe injection practice is one of the major contributors to new hepatitis C
virus (HCV) infections; thus, people who inject drugs are a key population to prioritize to …